The 6 most recent market catalysts affecting $PETS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 11, 2026
Corporate Catalyst
Bearish
Impact 85
PetMed Express, Inc. Reports Financial Results for Second Quarter Ended September 30, 2026
PetMed Express (PETS) reported a substantial 19.4% drop in Q2 2026 net sales, falling to $35.8 million from $44.4 million in the prior year. This decline, attributed to lower presc…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 65
PetMeds Announces Strategic Partnership with Pet Supermarket
PetMeds (PETS) has announced a significant strategic partnership with Pet Supermarket, marking its second large-scale white-label pharmacy program. This collaboration allows PetMed…
Sep 25, 2026
Corporate Catalyst
Bearish
Impact 55
Morgan Stanley Maintains Underweight on PetMed Express, Lowers Price Target to $1.4
Morgan Stanley's analyst Erin Wright maintained an 'Underweight' rating on PetMed Express (PETS) and substantially reduced the price target from $2.15 to $1.4. This action indicate…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 75
PetMed Express Announces Appointment Of Jeff Willard As CEO And President Effective September 28; Leslie C.G. Campbell To Retire As Board Chair, Justin Mennen To Succeed Her
The appointment of a new CEO and President, Jeff Willard, at PetMed Express (PETS) is a significant corporate catalyst. New leadership often brings fresh perspectives, strategic sh…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 75
PetMed Express shares are trading lower after the company reported mixed Q1 financial results.
The lower trading of PetMed Express shares is a direct consequence of its mixed Q1 financial results, which likely included some underperforming metrics or a weaker outlook that di…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 65
PetMeds Announces Proposed Sale-Leaseback Of Delray Beach, FL Buildings For $37M
This sale-leaseback transaction for PetMeds (PETS) is a corporate catalyst, primarily impacting the company itself. The $37 million cash infusion will significantly boost its balan…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.